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Abstract
Purpose—Chemotherapy-induced nausea and vomiting (CINV) is a major concern for cancer 
patients and, if uncontrolled, can seriously compromise quality of life (QOL) and other treatment 
outcomes. Because of the expense of antiemetic medications used to prevent CINV (particularly 
oral medications filled through Medicare Part D), disparities in their use may exist.
Methods—We used 2006–2012 SEER-Medicare data to evaluate the use of neuroknin-1 receptor 
antagonists (NK1s), a potent class of antiemetics, among black and white women initiating highly 
emetogenic chemotherapy for the treatment of early-stage breast cancer. We used modified 
Poisson regression to assess the relationship between race and (1) any NK1 use, (2) oral NK1 
(aprepitant) use, and (3) intravenous NK1 (fosaprepitant) use. We report adjusted risk ratios (aRR) 
and 95% confidence intervals (CI).
Results—The study included 1,130 women. We observed racial disparities in use of any NK1 
(aRR: 0.68, 95% CI: 0.51–0.91) and in use of oral aprepitant specifically (aRR: 0.54, 95% CI: 
0.35–0.83). We did not observe disparities in intravenous fosaprepitant use. After controlling for 
variables related to socioeconomic status, disparities in NK1 and aprepitant use were reduced but 
not eliminated.
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Conclusions—We found racial disparities in women’s use of oral NK1s for the prevention of 
CINV. These disparities may be partly explained by racial differences in socioeconomic status, 
which may translate into differential ability to afford the medication.
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Introduction
Patients initiating cancer treatment have consistently cited chemotherapy-induced nausea 
and vomiting (CINV) as a major and fearful concern.[1] Poorly-controlled CINV can have 
severe physiological consequences, including dehydration, nutritional derangements, 
metabolic imbalances, and anorexia.[2] Thus, inadequate CINV control can lead to 
deterioration of a patient’s functional condition and quality of life (QOL). [3–5] Further, 
hospital admissions, emergency department (ED) visits, and outpatient hospital visits after 
the first cycle of chemotherapy are both common and costly, with one study estimating the 
cost of treating CINV between the first and second cycle at $5,299 among patients with a 
visit, and $731 across all patients receiving moderately or highly emetogenic chemotherapy.
[6] In addition, uncontrolled CINV can lead to decreased chemotherapy adherence or even 
withdrawal from potentially beneficial chemotherapy.[2,7] CINV control is therefore a 
critical aspect of high-quality cancer care and has profound implications for patients’ cancer 
care experience.
Oncology professional organizations produce and endorse clinical practice guidelines for the 
use of antiemetics to prevent CINV.[8–10] For several years, the guidelines have 
recommended prophylactic use of the most potent class of antiemetic, neurokinin-1 recetpor 
antagonists (NK1s), for patients receiving highly-emetogenic chemotherapy. Until 2008, 
aprepitant, an oral formulation, was the only NK1 available for CINV prophylaxis. Barriers 
to aprepitant use exist. First, in many cases, patients are required to fill a prescription for 
aprepitant at their home pharmacy, rather than receive it in the clinic at the time of their 
chemotherapy infusion. Second, the drug is expensive relative to other antiemetics, and 
patients may be subject to high cost sharing, particularly when the drug is filled at a 
pharmacy and reimbursed under Medicare Part D. Estimates suggest that three aprepitant 
capsules cost over $500 under Medicare Part D, and patients may be responsible for 25 to 50 
percent of that cost, depending on their phase of the Part D benefit (i.e., in the initial 
coverage phase or in the doughnut hole, respectively).[11]
Evidence suggests that cost and access barriers may disproportionately affect minority 
patients. Studies of patients with lung, prostate, and colorectal cancers have shown black 
race to be negatively associated with use of other antiemetic drugs.[12,13] Whether this 
finding extends to NK1s and to other cancers is unknown. Assessing the relationship 
between race and NK1 use among breast cancer patients is particularly important, as this 
population frequently receives highly emetogenic chemotherapy. As well, research has 
demonstrated that black breast cancer patients may be more likely than white patients to 
have gaps in, or discontinue use of, chemotherapy because of hospitalizations and acute 
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illness [14] possibly due to adverse effects of treatment. In general, minority cancer patients 
are more likely than white patients to experience uncontrolled symptoms and to report 
inadequate supportive care for pain and psychosocial symptoms.[15–19] As a first step 
towards understanding how the quality of CINV prophylaxis may contribute to racial 
disparities in breast cancer care, we assessed potential racial disparities in prophylactic use 
of NK1s among early-stage breast cancer patients beginning a chemotherapy regimen for 
which use of an NK1 is guideline-recommended. We were also interested to learn whether 
disparities were attenuated by intravenous (versus oral) NK1 use.
Methods
Data
We used the National Cancer Institute’s Surveillance Epidemiology and End Result (SEER) 
database linked with Medicare fee-for-service claims from 2006–2012. The SEER program 
consists of population-based cancer registries and represents 28% of the population with 
cancer. SEER data are merged with fee-for-service Medicare claims to allow for assessments 
of health services use among Medicare beneficiaries with cancer.[20] Our study was 
conducted in accordance with a SEER-Medicare data use agreement and was approved by 
the Institutional Review Board at the University of North Carolina at Chapel Hill.
Sample
We included women aged 65 years and older who were diagnosed with stage I, II, or III 
breast cancer between January 1, 2007 and December 31, 2011 (Figure 1). Eligible women 
were: (1) not diagnosed at autopsy or death; (2) continuously enrolled in Medicare Parts and 
A and B for 6 months before and 12 months after diagnosis; (3) continuously enrolled in 
Medicare Part D for 12 months after diagnosis; and (4) not enrolled in an HMO for 6 months 
before and 12 months after diagnosis. There were 27,160 women meeting these criteria. 
From this sample, we restricted our study to women who received surgery (mastectomy or 
breast conserving surgery) and initiated chemotherapy within 6 months of diagnosis 
(n=4,651). The analysis was further restricted to women whose first cycle of adjuvant 
chemotherapy included an anthracycline and cyclophosphamide (n=1,569), as guidelines 
have consistently recommended use of an NK1 for these regimens throughout the study 
period.[9,21,22,8,10] Our sample was limited to women initiating adjuvant chemotherapy 
following surgery (versus women receiving neoadjuvant chemotherapy) in an effort to make 
the sample as homogenous as possible with regard to treatment experiences and potential 
unmeasured confounders. Because of the small proportion of non-black minorities (n=118), 
the study was restricted to black and white women (n=1,451). Finally, we restricted our 
sample to women who initiated chemotherapy on or after February 1, 2007, so that we could 
observe Part D prescription drug claims for antiemetics in the 30 days before chemotherapy 
initiation (n=1,130).
Variables
Our primary outcome was patients’ use of an NK1 during the first cycle of adjuvant 
chemotherapy. NK1 users were defined as having a Medicare Part D claim for aprepitant 
(oral formulation), as identified by the drug name, in the 30 days before or on the day of 
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chemotherapy initiation. Alternatively, they had a Part B claim for aprepitant in the 30 days 
before or on the day of chemotherapy initiation, as identified using Health Care Common 
Procedure Coding System codes (J8501) and as recorded in the outpatient, physician 
services or durable medical equipment claims files. Finally, NK1 users could have a claim 
for fosaprepitant (IV formulation) (C9242, J1453) on the day of chemotherapy initiation, as 
recorded in the outpatient or physician services files.
Our main independent variable was race (black or white), as reported in the Patient 
Entitlement and Diagnosis Summary File. Covariates included patients’ demographic and 
clinical characteristics: age, cancer stage, tumor grade, hormone receptor status, lymph node 
involvement, and comorbid illness (calculated using the Klabunde modification of the 
Charlson score based on patients’ Medicare Part A and B claims pre-diagnosis).[23] We also 
measured marital status and receipt of a low-income subsidy to assist with prescription drug 
costs (i.e. Medicaid dual eligibility and/or “extra help” through the Medicare Part D 
program). Although patients dually eligible for Medicare and Medicaid receive subsidies to 
assist with drug co-pays, their prescription drugs are typically covered under Medicare Part 
D versus Medicaid. Other measures of socioeconomic status (SES) included census tract-
level high school completion rate and median income, obtained from the 2000 census. 
Geographic variables were U.S. region of residence, and extent of urbanization at patients’ 
residences.
Statistical Analysis
We compared the distributions of patient characteristics between racial groups using chi-
squared tests. To directly estimate relative risk with robust error variance, we used modified 
Poisson regression[24] to assess the relationship between race and NK1 use controlling for 
pre-specified patient characteristics. Because black women are disproportionately likely to 
receive drug copay assistance through Medicaid dual eligibility or a Part D low-income 
subsidy,[25,26] we included a drug copay assistance indicator and an interaction of race and 
copay assistance in our primary models to determine whether the models should be stratified 
by drug copay assistance receipt. Because the interaction effect was not statistically 
significant, we present the main effects models. Specifically, we present risks and adjusted 
risk ratios (aRR) with 95% confidence intervals (CI) for NK1 use, comparing black and 
white women. We estimated separate models for any NK1 use, aprepitant use, and 
fosaprepitant use. Because fosaprepitant was not approved by the FDA until 2008, this 
model was limited to patients who initiated chemotherapy in 2009 or later (N=524).
Accounting for Socioeconomic Status—The Institute of Medicine (IOM) defines 
racial healthcare disparities as differences in treatment not justified by racial differences in 
health status or preferences. [27] Analytic approaches to implement this definition of 
disparities use statistical models that control only for differences in health status (e.g. co-
morbidity, age), clinical need (e.g., tumor characteristics) and, if available, preferences for 
care, between racial groups.[13,28,29] This approach recognizes the mediating role of an 
individual’s SES and SES-related factors, as minorities tend to have lower SES profiles than 
whites, and such differences can impact care received. Therefore, the IOM’s model does not 
adjust for SES-related factors, as doing so may reduce or eliminate the estimated 
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independent effect of race on care and give a false picture of the care experience of 
vulnerable patients. In accordance with the IOM definition of health care disparities, our 
primary models adjusted for clinical characteristics, namely: age, year of chemotherapy 
initiation, tumor characteristics, and medical comorbidity.[29] In secondary analyses we 
assessed whether our findings would differ when including census tract-level SES, marital 
status, or geography in the primary model.
Sensitivity Analyses
In an exploratory model, we excluded tumor characteristics, since these factors should not 
influence a patient’s need for antiemetics. Further, because advanced stage at diagnosis, 
[30,31] hormone receptor negative phenotype, and high grade are more common in black 
women,[30,32] including these covariates might actually attenuate the effect of race on 
likelihood of receiving CINV prophylaxis. Results from these analyses were consistent with 
the primary analysis and are not shown.
Results
Among the 1,130 women who met our eligibility criteria, 1,015 (89.8%) were white. 
Compared to white women, black women were less likely to be married (25% versus 53%) 
and more likely to receive drug copay assistance through Medicaid or Medicare Part D (70% 
versus 21%). There were also racial differences in census tract-level income and education 
and U.S. region of residence (see Table 1).
In the unadjusted analyses, we found statistically significant racial differences in women’s 
use of any NK1 (41% white vs. 28% black; p<0.01) and aprepitant use (29% white vs. 16% 
black, p<0.01), but not in fosaprepitant use (15% white vs. 12% black, p=0.41). Unadjusted 
associations of each covariate with NK1, aprepitant, and fosaprepitant use are shown in 
Appendix Table 1.
In models adjusting for clinical characteristics only, racial disparities remained in use of any 
NK1 (aRR: 0.68, 95% CI: 0.51–0.91) and aprepitant (aRR: 0.54, 95% CI: 0.35–0.83). The 
relationship between race and fosaprepitant use was non-significant (aRR: 0.82, 95% CI: 
0.51–1.33) (see Table 2). Secondary models that included measures of SES (census tract-
level income and education and drug copay assistance receipt), marital status, and 
geographic factors were consistent with our primary models; however, estimates were no 
longer statistically significant. Being black reduced the risk of using any NK1 by 19% (aRR: 
0.81, 95%CI: 0.60–1.10; NS) and aprepitant by 32% (aRR: 0.66 95% CI: 0.43–1.104; NS)) 
(see Table 2).
Discussion
Among women initiating highly emetogenic chemotherapy containing an anthracycline and 
cyclophosphamide for their early-stage breast cancer, we observed that black women had a 
32% decreased risk of using any NK1 for the prevention of CINV. When examining oral and 
intravenous NK1 formulations separately, black women had a 46% decreased risk of 
receiving oral aprepitant. We did not observe a statistically significant racial difference in 
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women’s receipt of intravenous fosaprepitant. When we added SES- and geography-related 
variables to our models, the relationships between race and NK1 use and race and aprepitant, 
the effect estimates remained consistent with disparities, but were no longer statistically 
significant.
Despite clinical guidelines recommending the use of NK1s for anthracycline and 
cyclophosphamide-containing breast cancer regimens throughout the study period, only 40% 
of women in our sample used an NK1, according to our definition of prophylactic use. This 
may be due to a lack of provider familiarity with recommendations for NK1s for the 
chemotherapy regimens we examined, or institutional policies’ failure to include NK1s in 
the antiemetic order sets for these chemotherapy regimens. Although guidelines have 
consistently recommended use of an NK1 for anthracycline- and cyclophosphamide-
containing breast cancer regimens throughout our study period, in earlier guidelines, these 
regimens were classified as “moderately” emetogenic; later in the study period, guideline 
updates reclassified the regimens as “highly” emetogenic.[8–10] This explanation is 
consistent with the substantial increase in NK1 use over time that we observed.
Our finding of a disparity is consistent with the limited research to date examining variation 
in use of antiemetics for CINV prevention. However, to our knowledge, our study is the first 
to include NK1s. In the only study to date that specifically investigated racial disparities in 
antiemetic use, Samuel et al. focused on patients with colorectal, prostate, and lung cancers 
in the Veterans Affairs system. Although they documented disparities in use of some 
antiemetics, their data were from the early 2000s, before NK1s were recommended by 
clinical guidelines for the prevention of CINV.[13] Gomez and colleagues explored patterns 
of guideline-concordant antiemetic use among lung cancer patients. Although not focused 
on disparities, the authors demonstrated racial and income differences in antiemetic use. 
However, this study was limited to a single state’s cancer registry and did not include NK1s 
in the analysis.[12]
Our study is also the first of which we are aware to examine patterns of use of oral versus 
intravenous NK1s. It is important to distinguish between formulations because many 
patients are required to fill a prescription for oral aprepitant, a high-cost medication, at their 
home pharmacy. Under Medicare Part D, patients may be subject to high cost sharing. The 
introduction of intravenous fosaprepitant in 2008 may have helped obviate access and cost 
barriers related to use of oral therapy. Specifically, because fosaprepitant is administered in 
the clinic, it is covered under Medicare Part B. Although Part B tends to have 20% co-
insurance for all services, the large majority of Medicare beneficiaries have supplemental 
insurance coverage to assist with their out-of-pocket Part B costs.[33] Our identification of 
racial disparities in oral, but not intravenous, NK1 use supports the hypothesis that 
fosaprepitant is more affordable and accessible for patients. However, it is important to 
acknowledge that the lack of an observed disparity in fosaprepitant use could be due to 
insufficient sample size, as the fosaprepitant models were limited to patients who initiated 
chemotherapy in 2009 or later (N=524).
Two potential explanations for our observation of disparities in aprepitant use are that black 
women are: (1) equally as likely as white women to be prescribed aprepitant, but less likely 
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to fill their prescriptions, possibly due to financial or other access barriers or (2) 
disproportionately likely to see providers who do not prescribe NK1s in accordance with 
clinical guidelines, because they are more likely to be treated in lower-performing settings.
[34,13] Both explanations seem plausible given our findings. Specifically, the fact that 
disparities in NK1 and aprepitant use were somewhat attenuated when SES-related factors 
were added to the models suggests that the disparities are at least partly explained by SES 
differences between black and white women. These SES differences could translate into 
differential ability to pay for prescription drugs, or differential access to high-quality care 
(including guideline-adherent antiemetic prescribing).[34,13] Interestingly, geographic 
region also appeared to partly attenuate disparities, suggesting a potential role for 
geographic variation in prescribing in explaining disparities in NK1 use.
Also of note, unlike prior reports, receipt of drug copay assistance appeared to act as an 
indicator of low income, rather than as an indicator of increased ability to pay for 
prescription drugs. Specifically, recent work by Neuner and Biggers documented a positive 
effect of drug copay assistance receipt on breast cancer patients’ adherence to aromatase 
inhibitors.[35,25] In contrast, we observed a negative effect of drug copay assistance receipt 
on aprepitant use. One possible explanation for this difference may be our measure of drug 
copay assistance receipt, which combined assistance through Medicaid dual eligibility and 
the Part D low-income subsidy (i.e., a woman was said to be a drug copay assistance 
recipient if she received either type of assistance), whereas Neuner’s and Biggers’ studies 
measured only Part D low-subsidy receipt. Our results may reflect the mixed effect of dual 
eligibility status, which could be an indicator of decreased access, and Part D low-income 
subsidy receipt, which has been demonstrated to improve adherence.
Our study had several limitations. First, we focused on fee-for-service Medicare 
beneficiaries with Part D coverage. It is unknown whether our findings generalize to 
younger women, Medicare beneficiaries enrolled in an HMO or women without prescription 
drug coverage through Part D. Second, in our secondary models, we may have misclassified 
individuals’ SES by using area-level measures of SES.[36,37] Third, because of the limited 
number of minority women represented in SEER-Medicare, we may have lacked statistical 
power for some comparisons. This is particularly true of the fosaprepitant models, which 
were limited to the 524 women who initiated chemotherapy in 2009 or later. Fourth, our use 
of Medicare administrative claims data for this analysis may have resulted in our under-
capturing of NK1 use overall if these medications were provided in clinic and not billed to 
Medicare. However, we do not believe that capture issues would differentially affect black 
versus white patients, so comparisons between groups should be valid nonetheless. Fifth, 
with claims data, we could not separate physicians’ failure to prescribe aprepitant from 
patients not filling prescriptions. Thus, although we have documented the existence of 
disparities, we are unable to identify the underlying causes of the observed disparities using 
SEER-Medicare data. Future studies should attempt to use clinical data to ascertain whether 
the disparities identified here reflect disparities in NK1 prescriptions or fills. If black and 
white women are equally likely to be prescribed NK1s but less likely to fill these 
prescriptions, disparities may in fact reflect barriers related to affordability and accessibility.
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Although our study and others have pointed to racial disparities in use of antiemetics to 
prevent CINV, it remains unclear whether such disparities contribute to the disparate 
outcomes of black and white cancer patients. In breast cancer, black-white disparities in 
systemic treatment adherence and survival have been documented. [38–40,14] Future studies 
should assess the role of treatment-induced side effect (including CINV) prevention and 
management in contributing to potential disparities not only in these observed outcomes but 
also in patients’ quality of life and cancer care experience.
Our findings suggest that there may be a need for increased awareness among oncology 
providers of potential barriers to obtaining oral medications for CINV prevention. As well, 
our data point to several possible explanations for and points of intervention to reduce 
disparities. For example, disparities may stem from low income and minority patients’ 
difficulty accessing or affording oral aprepitant, in which case the IV formulation may be 
more appropriate. Disparities may also stem from variation in prescribing, in which case 
provider-targeted interventions may help to reduce disparities. To inform specific solutions, 
further research is needed to determine the relative contribution of patient, provider, and 
system level factors to disparities.
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Table 1
Sample Characteristics, by Race
White Black p-value
Number of Patients 1,015 115
Demographic Characteristics
Age at Cancer Diagnosis
 65–66 20.7 25.2 0.7
 67–68 24.7 24.4
 69–71 25.1 22.6
 72–91 29.4 27.8
Marital Status at Diagnosisa
 Married/Partnered 52.9 25.2 <0.0001
 Non Married/Partnered 42.5 --
 Unknown 4.6 --
Median Household Income in Census Tract of Residencea
 Quartile 1: $0–32,791 21.6 53.0 <0.0001
 Quartile 2: $32,972–44,039 25.5 --
 Quartile 3: $44,040–58,436 -- 13.0
 Quartile 4: $58,437–188,340 27.1 --
 Unknown -- 0
Proportion of Adult Residents with No High School Degree in Census Tract of Residencea
 Quartile 1: 1.22–9.69% 27.4 -- <0.0001
 Quartile 2: 9.70–16.57% 26.7 --
 Quartile 3: 16.58–27.88% -- 30.4
 Quartile 4: 27.89–75.17% 20.3 57.4
 Unknown -- 0
Drug Copay Assistance (Medicaid Dual Eligibility and/or Part D Low Income Subsidy)
 Yes 21.1 69.6 <0.0001
 No 78.9 30.4
Residence
 Metropolitan County 74.8 82.6 0.06
 Non-Metropolitan County 25.1 16.4
U.S. Region
 Northeast 19.4 20.0 <0.0001
 Midwest 18.0 14.8
 West 37.4 14.8
 South 25.1 50.4
Clinical Characteristics
Year of Chemotherapy Initiationa,c
 2007 28.9 31.3 0.9
 2008 20.1 20.9
 2009 17.0 18.3
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White Black p-value
 2010 14.8 11.3
 2011 15.4 14.8
 2012 3.8 --
Charlson Comorbidity Score
 0 78.4 75.7 0.2
 1 17.2 16.5
 >1 4.3 --
Cancer Stage
 Stage I 12.8 10.4 0.7
 Stage II 53.6 56.5
 Stage III 33.6 33.0
Hormone Receptor Statusa
 HR positive 67.0 62.6 0.5
 HR negative 28.7 --
 Unknown 3.7 --
Tumor Gradea
 Low 10.3 -- 0.3
 Intermediate 40.1 33.9
 High 45.9 56.5
 Unknown 4.3 --
Lymph Node Involvement
 Yes 70.9 67.0 0.06
 No 27.7 --
 Uknown 1.4 --
a
Cell sizes including proportions reflecting Ns<11 or information that would allow Ns<11 to be derived were suppressed (--) to protect patients’ 
identities.
b
“Partnered” refers to “Unmarried or domestic partner” as documented in the Patient Entitlement and Diagnosis Summary File of SEER-Medicare.
c
A small proportion of patients initiated chemotherapy in 2012 because we only have SEER data on patients diagnosed through December 2011. 
Thus, only patients who received chemotherapy within the first 6 months of 2012 are included in our sample.
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Table 2
Adjusted Risks and Risk Ratios of Any NK1 Use, Aprepitant Use, and Fosaprepitant Use
Primary Models (adjusting for clinical 
characteristics only)a
Secondary Models (adjusted for SES-
related variables)a
Estimate and 95% CI Estimate and 95% CI
Risk NK1 use, white 0.30 (0.20–0.44) 0.37 (0.21–0.63)
Risk NK1 use, black 0.21 (0.13–0.33) 0.30 (0.16–0.55)
Risk ratio NK1 use, black v. white 0.68 (0.51–0.91) 0.81 (0.60–1.10)
Risk aprepitant use, white 0.29 (0.18–0.46) 0.36 (0.18–0.55)
Risk aprepitant use, black 0.15 (0.08–0.30) 0.24 (0.10–0.55)
Risk ratio aprepitant use, black v. white 0.54 (0.35–0.83) 0.66 (0.43–1.04)
Risk fosaprepitant use, whitec 0.25 (0.13–0.50) 0.25 (0.09–0.70)
Risk fosaprepitant use, blackc 0.21 (0.10–0.45) 0.26 (0.09–0.82)
Risk ratio fosaprepitant use, black v. whitec 0.82 (0.51–1.33) 1.05 (0.62–1.76)
a
The primary models adjusted for patient age at diagnosis, year of chemotherapy initiation, and tumor characteristics. The secondary models 
adjusted for the same variables, in addition to census tract-level measures of income and education, receipt of drug copay assistance, marital status, 
U.S. region of residence, and the extent of urbanization at patients’ residences.
b
Estimates in bold are statistically significant at the p<0.05 level.
c
The fosaprepitant models were limited to patients initiating chemotherapy in or after 2009 (N=524).
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